AdvaMed Cautions FDA Against Rush To “Primary Mode of Action” Rule
This article was originally published in The Gray Sheet
Executive Summary
FDA should issue draft guidance defining "primary mode of action" before moving forward with rulemaking to codify the term, according to AdvaMed